USOO95931 64B2 (12) United States Patent (10) Patent No.: US 9,593,164 B2 Chiu et al. (45) Date of Patent: Mar. 14, 2017 (54) BISPECIFIC EGFR/C-MET ANTIBODIES 5,403.484 A 4/1995 Ladner et al. 5,427,908 A 6/1995 Dower et al. 5,558,864 A 9/1996 Bendig et al. (71) Applicant: Janssen Biotech, Inc., Horsham, PA 5,571,698 A 11/1996 Ladner et al. (US) 5,580,717 A 12/1996 Dower et al. 5,885,793 A 3, 1999 Griffiths et al. (72) Inventors: Mark Chiu, Spring House, PA (US); 5,891,996 A 4, 1999 Mateo de Acosta del Rio et al. Sheri Moores, Spring House, PA (US); 5,969,108 A 10/1999 McCafferty et al. 6,172,197 B1 1/2001 McCafferty et al. Joost Neijssen, Ultrecht (NL); Paul 6,521.404 B1 2/2003 Griffiths et al. Parren, Ultrecht (NL); Janine 6,544,731 B1 4/2003 Griffiths et al. Schuurman, Ultrecht (NL) 6,555,313 B1 4/2003 Griffiths et al. 6,582,915 B1 6/2003 Griffiths et al. (73) Assignee: Janssen Biotech, Inc., Horsham, PA 6,593,081 B1 7/2003 Grigg et al. 6,737,056 B1 5, 2004 Presta (US) 7,247.301 B2* 7/2007 van de Winkel et al. 424/130.1 7,589, 180 B2 9, 2009 Old et al. (*) Notice: Subject to any disclaimer, the term of this 7,595,378 B2 9, 2009 van de Winkel et al. patent is extended or adjusted under 35 2004O166544 A1 8, 2004 Morton et al. U.S.C. 154(b) by 0 days. 2004/O197332 A1 10, 2004 Ulrich et al. 2005/0118643 A1 6/2005 Burgess et al. 2005/0272083 A1 12/2005 Seshagiri (21) Appl. No.: 14/086,588 2009/0042906 A1 2/2009 Huang et al. 2009,0182127 A1 7/2009 Kjaergaard et al. (22) Filed: Nov. 21, 2013 2010.0015133 A1 1/2010 Igawa et al. 2010, 0028637 A1 2/2010 Tavsanli et al. (65) Prior Publication Data 2010/0254989 A1 * 10/2010 Bossenmaier et al. .... 424,136.1 2011/0091372 A1 4/2011 Ghayur et al. US 2014/014 1000 A1 May 22, 2014 2011/0097.262 A1 4/2011 Goetsch et al. 2011 0123532 A1 5/2011 Gurney et al. Related U.S. Application Data 2011/0256142 A1 10, 2011 Van De Winkel et al. 2012/0149876 A1 6/2012 Von Kreudenstein et al. (60) Provisional application No. 61/728,912, filed on Nov. 2013,0195849 A1 8/2013 Spreter Von Kreudenstein et al. 21, 2012, provisional application No. 61/782.550, filed on Mar. 14, 2013, provisional application No. FOREIGN PATENT DOCUMENTS 61/809,541, filed on Apr. 8, 2013, provisional application No. 61/864,717, filed on Aug. 12, 2013, WO WO O2/100348 A2 12/2002 WO WO 2005/O16382 A1 2, 2005 provisional application No. 61/892.797, filed on Oct. WO WO 2006/O15371 A2 2, 2006 18, 2013. WO WO 2006/028936 A2 3, 2006 (51) Int. Cl. (Continued) C07K 6/28 (2006.01) A 6LX 39/395 (2006.01) OTHER PUBLICATIONS A 6LX 3/57 (2006.01) Adjei, et al., “Early Clinical Development of ARQ 197, a Selective, A6 IK 45/06 (2006.01) Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase A6 IK 3L/4545 (2006.01) for the Treatment of Advanced Cancers,” the Oncologist, 16: A6 IK 3/437 (2006.01) 788-799 (2011). A 6LX 3/5.377 (2006.01) Amado, et al., “Wild-Type KRAS Is Required for Panitumumab A6 IK 33/24 (2006.01) Efficacy in Patients With Metastatic Colorectal Cancer,” Journal of A61 K 39/00 (2006.01) Clinical Oncology, 26(10): 1626-1634 (2008). (52) U.S. Cl. Baselga, et al., “Critical Update and Emerging Trends in Epidermal CPC ........ C07K 16/2863 (2013.01); A61K 31/437 Growth Factor Receptor Targeting in Cancer,” Journal of Clinical Oncology, 23(11): 2445-2459 (2005). (2013.01); A61K 31/4545 (2013.01); A61 K Batley, et al., “Inhibition of FGF-1 Receptor Tyrosine Kinase 31/517 (2013.01); A61 K3I/5377 (2013.01); Activity by PD 161570, a New Protein-Tyrosine Kinase Inhibitor.” A61K 33/24 (2013.01); A61K 39/395 Life Sciences, 62(2): 143-150 (1998). (2013.01); A61K 39/3955 (2013.01); A61 K Bean, et al., “MET amplification occurs with or without T790M 45/06 (2013.01); A61 K 2039/505 (2013.01); mutations in EGFR mutant lung tumors with acquired resistance to C07K 23.17/31 (2013.01); C07K 2317/73 gefitinib or erlotinib,” Proceedings of the National Academy of (2013.01); C07K 2317/76 (2013.01); C07K Science, 104(52): 20932-20937 (2007). 23 18/20 (2013.01) (Continued) (58) Field of Classification Search None Primary Examiner — Ruixiang Li See application file for complete search history. (74) Attorney, Agent, or Firm — Kirk Baumeister (56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS Bispecific EGFR/c-Met antibodies and methods of making and using the molecules. 5,212.290 A 5/1993 Vogelstein et al. 5,223,409 A 6, 1993 Ladner et al. 2 Claims, 18 Drawing Sheets US 9,593.164 B2 Page 2 (56) References Cited Ichimura, et al., “Expression of c-met/HGF Receptor in Human Non-Small Cell Lung Carcinomas in vitro and in vivo and Its FOREIGN PATENT DOCUMENTS Prognostic Significance.” Japan Journal of Cancer Research, 87: 1063-1069 (1996). WO WO 2008/O77546 A1 T 2008 Jänne, et al., “Effect of Epidermal Growth Factor Receptor Tyrosine WO WO 2008, 127710 A2 10, 2008 Kinase Domain Mutations on the Outcome of Patients with Non WO WO 2009/03O239 A1 3, 2009 Small Cell Lung Cancer Treated with Epidermal Growth Factor WO WO 2009/085462 A1 T 2009 Receptor Tyrosine Kinase Inhibitors.” Clinical Cancer Research, WO WO 2009, 111691 A2 9, 2009 12(14 Suppl): 4416s-4420s (2006). WO WO 2009.126834 A2 10, 2009 WO WO 2010/039248 A1 4/2010 Knappik, et al., “Fully Snythetic Human Combinatorial Antibody WO WO 2010/115551 A1 10, 2010 Libraries (HuCAL) Based on Modular Consensus Frameworks and WO WO 2011 110642 A2 9, 2011 CDRs Randomized with Trinucleotides,” Journal of Molecular WO WO 2011110642 A2 * 9, 2011 Biology, 296: 57-86 (2000). WO WO 2011 131746 A2 10, 2011 Konno, et al., “Fucose content of monoclonal antibodies can be WO WO 2012/042026 A1 4/2012 controlled by culture medium osmolality for high antibody-depen WO WO 2014/081944 A2 5, 2014 dent cellular cytotoxicity,” Cytotechnology, 64; 249-265 (2012). Krebs, et al., “High-throughput generation and engineering of OTHER PUBLICATIONS recombinant human antibodies,” Journal of Immunological Meth Cappuzzo, et al., “Epidermal Growth Factor Receptor Gene and ods, 254: 67-84 (2001). Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer.” Lièvre, et al., "KRAS Mutations. As an Independent Prognostic Journal of the National Cancer Institute, 97: 643-655 (2005). Factor in Patients with Advanced Colorectal Cancer Treated with Christensen, et al., “c-Met as a target for human cancer and Cetuximab,” Journal of Clinical Oncology, 26(3): 374-379 (2008). characterization of inhibitors for therapeutic intervention.” Cancer Linardou, et al., “Somatic EGFR mutations and efficacy of tyrosine Letters, 225: 1-26 (2005). kinase inhibitors in NSCLC,” National Review of Clinical Oncol Cooper, et al., “Molecular cloning of a new transforming gene from ogy, 6: 352-366 (2009). a chemically transformed human cell line.” Nature, 311: 29-33 Li, et al., "Skin toxicities associated with epidermal growth factor (1984). receptor inhibitors.” Target Oncology, 4: 107-119 (2009). Dall'Acqua, et al., “Properties of Human IgGls Engineered for Livingston et al., NIEHS-SNPs, environmental genome project, Enhanced Binding to the Neonatal Fc Receptor (RcRN).” The NIEHS ES15478, http://egp.gs.washington.edu. Journal of Biological Chemistry, 28.1(33): 23514-23524 (2006). Määttä, et al., “Proteolytic Cleavage and Phosphorylation of a DeRoock, et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA Tumor-associated EfbB4 Isoform Promote Ligand-independent mutations on the efficacy of cetuximab plus chemotherapy in Survival and cancer Cell Growth.” Molecular Biology, 17: 67-79 chemotherapy-refractory metastatic colorectal cancer: a retrospec (2006). tive consortium analysis.” Lancet Oncology, 11: 753-762 (2010). Ma, et al., “c-Met: Structure, functions and potential for therapeutic Downward, et al., “Autophospholylation sites on the epidermal inhibition.” Cancer and Metastasis Reviews, 22:309-325 (2003). growth factor receptor,” Nature, 311: 483-485 (1984). Marks, et al., “By-passing Immunization Human Antibodies from Engelman, et al., “MET Amplification Leads to Gefitinib Resistance V-gene Libraries Displayed on Phage,” Journal of Molecular Biol in Lung Cancer by Activating ERBB3 Signaling.” Science, 316: ogy, 222:581-597 (1991). 1039-1043 (2007). Mendelsohn, et al., “Epidermal Growth Factor Receptor Targeting Kathryn M. Ferguson, "Structure-Based View of Epidermal Growth in Cancer.” Seminars in Oncology, 33: 369-385 (2006). Factor Receptor Regulation.” Annual Review of Biophysics, 37: Mendelsohn, et al., “The EGF receptor family as targets for cancer 535-373 (2008). therapy.” Oncogene, 19: 6550-6565 (2000). Ferrara, et al., “Modulation of Therapeutic Antibody Effector Func Mori, et al., “Engineering Chinese Hamster Ovary Cells to Maxi tions by Glycosylation Engineering: Influence of Golgi Enzyme mize Effector Function of Produced Antibodies Using FUT8 Localization Domain and co-Expression of Heterologous 1, 4-N- siRNA.” Biotechnology and Bioengineering, 88(7): 901-908 acetylglucosaminyltransferase III and Golgi O-mannosidase II.” (2004). Biotechnology and Bioengineering, 93(5): 851-861 (2006). Nakata, et al., “Recent understanding of the molecular mechanisms Ferrara, et al., “The Carbohydrate at FcyRIIIa Asn-162.” The for the efficacy and resistance of EGF receptor-specific tyrosine Journal of Biological Chemistry, 281 (8): 5032-5036 (2006).